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Abstract. Background: COX-2 and VEGF are important triggers of colon cancer growth, metastasis and angiogenesis. Cox-2 pro-
moter contains transcriptional regulatory elements for AP-1 and NF-κB transcription factors whilst vegf is a known AP-1 down-
stream target gene. We investigated whether stromal myofibroblasts surrounding colon adenocarcinomas express COX-2 and
VEGF and whether activation of AP-1 and NF-κB, as well as expression of EGF-R parallel expression of COX-2 and VEGF in
these cells. Methods: Immunohistochemical methodology was performed on archival sections from 40 patients with colon adeno-
carcinomas. We evaluated c-FOS, p-c-JUN (phosphorylated c-JUN), p-IκB-α (phosphorylated IκB-α), EGF-R, COX-2, NF-κB
and VEGF expression in stromal myofibroblasts surrounding colon adenocarcinomas. Double immunostaining with a-smooth
muscle actin and each antibody was done to verify the expression of these molecules in stromal myofibroblasts. Results: VEGF,
p-IκB-α, NF-κB, c-FOS, p-c-JUN, EGF-R and COX-2 were expressed in stromal myofibroblasts surrounding colon adenocarci-
nomas in the majority of cases. EGF-R, p-IκB-α, NF-κB, c-FOS and p-c-JUN correlated positively with COX-2 and VEGF ex-
pression. Conclusion: Stromal myofibroblasts surrounding colon adenocarcinomas are an important source of VEGF and COX-2
production, while AP-1 and NF-κB transcription factors are activated and EGF-R is expressed in these cells and associated with
COX-2 and VEGF production.
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1. Introduction
Several studies in breast, colon and prostate carcino-
mas indicate that carcinogenesis is associated with pro-
gressive alterations in the functional interactions be-
tween the nascent tumor and its surrounding stroma
*P.A. Konstantinopoulos and G.P. Vandoros contributed equally
to this work.
**Corresponding author: Prof. Athanasios G. Papavassiliou,
Department of Biological Chemistry, Medical School, Univer-
sity of Athens, 75, M. Asias Street, GR-11527 Athens, Greece.
Tel.: +30 210 7462509; Fax: +30 210 7791207; E-mail:
papavas@med.uoa.gr
[1–3]. In that regard, stromal cells generate oncogenic
signals that mediate phenotypic and genomic changes
to the adjacent epithelial cells and promote tumor inva-
sion and metastasis [4]. One of the pivotal events that
highlight stromal remodeling is the transdifferentiation
of stromal cells to myofibroblasts [5]. Myofibroblasts
are unique smooth-muscle-like fibroblasts which pro-
duce various cytokines and growth factors that modu-
late epithelial and endothelial proliferation, apoptosis,
adhesion and migration.
Cyclooxygenase-2 (COX-2), epidermal growth fac-
tor (EGF) and vascular endothelial growth factor
(VEGF) have been conclusively shown to be expressed
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by epithelial cancer cells and to promote colon cancer
growth, metastasis and angiogenesis [6,7]. Cox-2 pro-
moter contains transcriptional regulatory elements for
activator protein-1 (AP-1) and nuclear factor kappa B
(NF-κB) transcription factors while vegf is a well
known AP-1 downstream target gene [8–11]. Although
the expression and effects of these factors on colon
cancer cells have been extensively studied, their ex-
pression and role on the stromal cells (particularly on
the stromal myofibroblasts) surrounding colon cancer
cells remain elusive. In this study we tested the hy-
pothesis that stromal myofibroblasts surrounding colon
adenocarcinomas express COX-2, VEGF and EGF re-
ceptor (EGF-R). Furthermore, since the transcription
factors AP-1 and NF-κB are known to upregulate tran-
scription of cox-2 and vegf genes we also investigated
whether activation of AP-1 and NF-κB occurs in stro-
mal myofibroblasts surrounding colon cancers.
To assess the activation of NF-κB pathway, we eval-
uated the expression of the NF-κB transcription fac-
tor as well as the expression of phosphorylated IκB-α
(p-IκB-α). NF-κB is retained to the cytoplasm in
an inactive state by binding to an inhibitory IκB-α
protein that blocks its nuclear localization sequence
(NLS) [12]. Multiple stimuli induce phosphorylation
of IκB-α at Ser32 leading to dissociation of NF-κB
from IκB-α, unmasking of its NLS and stimulation of
its transcriptional activity. In that regard, expression of
p-IκB-α correlates with activation of NF-κB pathway.
In the case of transcription factor AP-1, we examined
the expression of its constituents, c-FOS and phospho-
rylated c-JUN (p-c-JUN).
2. Materials and methods
2.1. Patient selection
Immunohistochemical methodology was performed
on formalin-fixed, paraffin-embedded sections from 40
consecutive patients with colon adenocarcinomas. The
age of the patients ranged from 45 to 90 years (mean
age: 72 years, SD = 9.8 years). Colon adenocarci-
nomas were classified as well, moderately and poorly
differentiated, according to standard pathologic crite-
ria. Staging was performed according to the American
Joint Committee on Cancer (AJCC) system.
2.2. Immunohistochemical methodology
Tissue specimens obtained from tumors were fixed
in 10% (v/v) buffered formalin and embedded in paraf-
fin. Serial 5-µm sections were obtained for staining
with hematoxylin and eosin and for immunohisto-
chemistry. The antibodies employed in the present
study, their sources and their characteristics are de-
picted in Table 1.
For transcription factors NF-κB and AP-1 (p-c-JUN,
c-FOS), nuclear staining suggests that they are in the
nucleus and their transcriptional activity is stimulated.
For p-IκB-α, cytoplasmic and nuclear staining sug-
gests that IκB-α is phosphorylated and thus inacti-
vated, which leads to translocation of NF-κB to the
nucleus and stimulation of its transcriptional activity.
For COX-2 and VEGF, cytoplasmic staining indicates
that these factors are expressed in the cells. Finally, for
EGF-R, membranic staining indicates that EGF-R is
expressed in the cells.
Microwave irradiation in 0.01 M citric buffer
(pH 6.0) was performed as antigen retrieval method
in all cases except for EGF-R. In the case of EGF-R,
enzymatic pretreatment with pepsin (DIGEST-ALL,
Zymed Laboratories Inc.) was done for 10 min in
37◦C. All primary antibodies were diluted with Chem-
Mate (DakoCytomation) antibody diluent and applied
on tissue sections for 30 min at room temperature.
Immunoreactivity was detected employing the En-
Vision (DakoCytomation) protocol in all cases except
Table 1
Sources and characteristics of antibodies used in the present study
Antibody Company Type Immunogen Dilution
c-FOS Santa Cruz Biotechnology Rabbit polyclonal Highly conserved domain of human c-FOS 1:80
p-c-JUN Santa Cruz Biotechnology Mouse monoclonal Amino acids 59-69 of human 1:80
c-JUN phosphorylated on Ser63
EGF-R Zymed Laboratories Inc. Mouse monoclonal Human EGF-R derived from A-431 cells 1:80
p-IκB-α Santa Cruz Biotechnology Mouse monoclonal Amino acid containing phosphorylated Ser32 of IκB-α 1:80
of human origin
COX-2 Assay Designs, Inc. Rabbit polyclonal Human COX-2 1:60
VEGF BD Biosciences Pharmingen Mouse monoclonal Native human VEGF, clone G153-694 1:100
NF-κB Santa Cruz Biotechnology Mouse monoclonal Amino acids 1-286 of human NF-κB p65 1:100
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for EGF-R. EGF-R immunopositivity was detected us-
ing the Super Picture Polymer Detection Kit (Zymed
Laboratories Inc.). Step sections were stained with all
antibodies and a-SMA (a-smooth muscle cell actin –
universal marker of myofibroblasts) and comparison of
staining results was performed.
2.3. Double immunostaining
To further verify that stromal myofibroblasts were
indeed expressing each of the molecular factors we
performed double immunostaining with the univer-
sal marker for myofibroblasts (a-smooth muscle actin/
a-SMA) as second primary antibody.
Following EnVision protocol and reaction with
DAB, slides were incubated with the second primary
antibody (a-SMA) for 25 min. Then, incubation with
EnVision Alkaline Phosphatase Kit (DakoCytomation)
for 25 min followed. Finally, reaction with FAST RED
chromogen from the same kit (DakoCytomation) for
20 min was performed. Sections from colon adenocar-
cinomas, in which the primary antibodies were omit-
ted, were used as negative controls.
2.4. Staining score and statistical analyses
Immunopositivity was graded according to the in-
tensity of the stain i.e. negative (0), weak (+1) and
strong (+2). This scale was used by two investi-
gators to evaluate and score all sections indepen-
dently without prior knowledge of the clinicopatho-
logical characteristics of each case. Specimens with
interobserver disagreement were reassessed by simul-
taneous examination by the two pathologists in a
double-headed light microscope. The correlation of
EGF-R, p-IκB-α, NF-κB, c-FOS and p-c-JUN expres-
sion with COX-2 and VEGF expression was assessed
by Kendall’s t coefficient. The level of expression of
all these factors was compared among the three adeno-
carcinoma differentiation degrees and the four AJCC
stages by nonparametric Kruskal–Wallis analysis of
variance (ANOVA). All analyses were performed us-
ing SPSS 9.0 for Windows.
3. Results
3.1. VEGF, p-IκB-α, NF-κB, c-FOS, p-c-JUN,
EGF-R and COX-2 are expressed in stromal
myofibroblasts surrounding colon
adenocarcinomas
VEGF and COX-2 were expressed in the cytoplasm
of stromal myofibroblasts in 80% of the patients and
Table 2
EGF-R, p-IκB-α, NF-κB, c-FOS, p-c-JUN, COX-2 and VEGF ex-
pression in the stroma of colon adenocarcinomas
Myofibroblasts Negative Weak (+1) Strong (+2)
COX-2 (N = 40) 6 (15%) 11 (27.5%) 23 (57.5%)
p-IκB-α (N = 40) 15 (37.5%) 7 (17.5%) 18 (45%)
EGF-R (N = 40) 14 (35%) 8 (20%) 18 (45%)
VEGF (N = 40) 8 (20%) 12 (30%) 20 (50%)
c-FOS (N = 40) 6 (15%) 8 (20%) 26 (65%)
NF-κB (N = 40) 14 (35%) 8 (20%) 18 (45%)
p-c-JUN (N = 40) 12 (30%) 19 (47.5%) 9 (22.5%)
85% of the cases, respectively. The active form of
c-JUN (p-c-JUN) was detected in the nuclei of stromal
myofibroblasts in 70% of the patients, while c-FOS
was expressed in the cytoplasm and nuclei of stromal
myofibroblasts in 85% of the patients. P-IκB-α was ex-
pressed in the cytoplasm and nuclei of stromal myofi-
broblasts in 62.5%, while NF-κB was expressed in the
cytoplasm and nuclei of stromal myofibroblasts in 75%
of the patients. Finally, membranic staining for EGF-R
was present in stromal myofibroblasts in 65% of the
cases. The immunohistochemistry results for COX-2,
p-IκB-α, NF-κB, EGF-R, VEGF, c-FOS and p-c-JUN
are presented in Table 2 and illustrated in Fig. 1. Stain-
ing in the cancer cells was also positive and correlated
with the staining of the stromal myofibroblasts in all
cases.
EGF-R, p-IκB-α, NF-κB, c-FOS, p-c-JUN, COX-2
and VEGF expression was observed in stromal my-
ofibroblasts surrounding colon adenocarcinomas re-
gardless of clinical stage and grade of differentia-
tion. Specifically, EGF-R, p-IκB-α, NF-κB, c-FOS,
p-c-JUN, COX-2 and VEGF expression in myofibrob-
lasts did not show any correlation with the staging or
differentiation of the adenocarcinomas.
3.2. EGF-R, p-IκB-α, NF-κB, c-FOS and p-c-JUN
correlate positively with COX-2 expression in
stromal myofibroblasts
The correlation of EGF-R, p-IκB-α, NF-κB, c-FOS
and p-c-JUN expression with COX-2 expression was
assessed by Kendall’s t coefficient. EGF-R, p-IκB-α,
NF-κB, c-FOS and p-c-JUN were statistically sig-
nificantly positively correlated with COX-2 expres-
sion (P < 0.001, P = 0.007, P < 0.001, P <
0.001, P < 0.001, respectively). These data indicate
that there is a coordinated upregulated expression of
EGF-R, p-IκB-α, NF-κB, c-FOS, p-c-JUN and COX-2
in stromal myofibroblasts surrounding colon adenocar-
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Fig. 1. Upper Panel: Myofibroblasts (black arrows) surrounding colon adenocarcinomas exhibiting p-c-JUN (A), c-FOS (B) and EGF-R (C) expression, respectively (×400). P-c-JUN, c-FOS
exhibit nuclear staining while EGF-R staining is membranic. Lower Panel: Double immunolabeling of stromal myofibroblasts with a-SMA (a-smooth muscle cell actin) and p-IκB-α (D),
VEGF (E) and COX-2 (F), respectively (×400). P-IκB-α (D), VEGF (E) and COX-2 (F) staining is brown while a-SMA staining is red in all cases. COX-2 and VEGF exhibit cytoplasmic
staining while p-IκB-α is nuclear and cytoplasmic.
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cinomas, implying that the activation of EGF-R, AP-1
and NF-κB is associated with increased expression of
COX-2 by these cells.
3.3. EGF-R, p-IκB-α, c-FOS and p-c-JUN correlate
positively with VEGF expression in stromal
myofibroblasts
As in the case of COX-2, EGF-R, p-IκB-α, NF-κB,
c-FOS and p-c-JUN were statistically significantly
positively correlated with VEGF expression (all P <
0.001). Kendall’s t coefficient was used for this analy-
sis. This result also suggests that coordinated activa-
tion of EGF-R, AP-1 and NF-κB is associated with
increased expression of VEGF by stromal myofibrob-
lasts surrounding colon adenocarcinomas.
4. Discussion
The present retrospective immunohistochemical
study demonstrated that myofibroblasts surrounding
colon adenocarcinomas express VEGF, p-IκB-α,
NF-κB, c-FOS, p-c-JUN, EGF-R and COX-2. More-
over, EGF-R, p-IκB-α, NF-κB, c-FOS and p-c-JUN
were positively correlated with VEGF and COX-2 in
a statistically significant manner. Our findings regard-
ing COX-2 are consonant with previous results re-
ported by Shattuck-Brandt et al., Adegboyega et al. and
by our group who also detected COX-2 expression in
stromal myofibroblasts surrounding colon adenocarci-
nomas [13–15]. To our knowledge, the present study
demonstrates for the first time that stromal myofibrob-
lasts also express VEGF, EGF-R, NF-κB, c-FOS and
p-c-JUN regardless of the stage and degree of differen-
tiation of the neoplasm.
Myofibroblasts are unique smooth muscle-like fi-
broblasts which play a central role in the stromal
changes associated with carcinogenesis [5]. In re-
sponse to cancer cell-derived cytokines such as trans-
forming growth factor-beta (TGF-b), fibroblasts differ-
entiate into myofibroblasts which secrete pro-invasive
signals that promote proliferation, mobility and in-
vasion of the adjacent epithelial cells. Expression of
COX-2 in myofibroblasts surrounding colon adenocar-
cinomas indicates that these cells may be responsible
for paracrine secretion of prostaglandins (PGs), espe-
cially PGE2. PGE2 is a well-known oncogenic signal
that promotes cancer cell proliferation and invasive-
ness and inhibits apoptosis [16]. Furthermore, PGE2
stimulates tumor angiogenesis via direct effects on en-
dothelial cells [16]. This evidence suggests that my-
ofibroblasts may occupy a central role in promoting
colon carcinogenesis by exerting significant paracrine
influence on adjacent epithelial and endothelial cells to
promote tumor invasiveness and angiogenesis, respec-
tively.
Expression of COX-2 in stromal myofibroblasts may
be induced by multiple stimuli. COX-2 behaves as an
immediate-early gene, which is subject to rapid reg-
ulation at the transcriptional level [8–11]. The cox-2
promoter contains transcriptional regulatory elements
for various transcription factors including NF-κB and
AP-1. The present study revealed a very strong cor-
relation between activation of NF-κB pathway and
COX-2 expression in stromal myofibroblasts, suggest-
ing that NF-κB pathway may constitute a major in-
ducer of cox-2 gene expression in these cells. Multi-
ple factors can potentiate NF-κB pathway in stromal
myofibroblasts. Interleukin-1 (IL-1) can induce cox-2
gene expression through activation of NF-κB pathway
in cultured human intestinal myofibroblasts [17]. Tu-
mor epithelial cell-derived TGF-b as well as expo-
sure to lipopolysaccharide (LPS) can also stimulate
activation of NF-κB pathway in target cells [18,19].
Furthermore, luminal bacterial components can acti-
vate intestinal myofibroblasts expressing toll-like re-
ceptors (TLRs) via induction of NF-κB pathway [20].
Phosphorylation of IκB-α to p-IκB-α is a critical step
in the activation of NF-κB pathway and is precisely
the point where non-steroidal anti-inflammatory drugs
(NSAIDs), which have been used for chemoprevention
against colon cancer, act to suppress NF-κB signaling
[21].
Our study also demonstrated that in stromal my-
ofibroblasts surrounding colon adenocarcinomas, ex-
pression of AP-1 constituents, p-c-JUN and c-FOS,
was statistically significantly correlated with expres-
sion of COX-2. Importantly, EGF-R expression was
also evident and paralleled both c-FOS/p-c-JUN and
COX-2 expression. EGF-R activates the membrane-
bound GTPase RAS, leading to activation of the ex-
tracellular signal-regulated kinase (ERK) and JUN
N-terminal kinase (JNK) signaling pathways [6].
Moreover, NF-κB is downstream of EGF-R. Our study
supports this orchestrated EGF-R, c-FOS, p-c-JUN and
NF-κB activation which is associated with expression
of COX-2 in these cells. Besides stromal myofibrob-
lasts, a similar orchestrated EGF-R, c-FOS, p-c-JUN,
NF-κB and COX-2 expression has also been shown in
colon cancer epithelial cells [22].
Similarly to COX-2, expression of VEGF was iden-
tified in stromal myofibroblasts surrounding colon ade-
nocarcinomas in the majority of cases. This novel find-
ing suggests that myofibroblasts may also be directly
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involved in promoting tumor angiogenesis via stim-
ulating adjacent endothelial cells. EGF-R, p-IκB-α,
c-FOS and p-c-JUN correlated positively with VEGF
expression in stromal myofibroblasts, indicating that
activation of EGF-R and of downstream NF-κB and
AP-1 may be associated with production of VEGF by
these cells.
In conclusion, the present study supports a pivotal
role of myofibroblasts in the stromal changes associ-
ated with colon carcinogenesis. Accordingly, we have
demonstrated that these cells are an important source
of VEGF and COX-2 production, which are both
known to exert powerful angiogenic, proinvasive and
growth-promoting effects. This study emphasizes that
the role of NF-κB, AP-1, EGF-R, COX-2 and VEGF
in colon carcinogenesis is not confined to the tumor
epithelial cells, but extends to the stroma, particularly
the stromal myofibroblasts that surround colon ade-
nocarcinomas. Our study supports that development
of NF-κB- and AP-1-targeted therapies (following
the paradigm of anti-EGF-R- and anti-VEGF-targeted
therapies) may be an important strategy against colon
cancer. Most importantly, our study raises the exciting
possibility that stromal myofibroblasts may be them-
selves important targets against colon carcinogenesis.
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